(R)-1-苯基-1,2,3,4-四氢异喹啉-2-甲酸乙酯 | 180468-41-1

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: (R)-1-苯基-1,2,3,4-四氢异喹啉-2-甲酸乙酯
• 英文名称: ethyl (R)-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate
• 英文别名: (1R)-ethyl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate；(R)-ethyl 1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate；ethyl (1R)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate
• CAS: 180468-41-1
• 化学式: C₁₈H₁₉NO₂
• 分子量: 281.354
• InChiKey: DKKVDRQVNMALLN-QGZVFWFLSA-N

物化性质

• 沸点：
  412.2±44.0 °C(Predicted)
• 密度：
  1.145

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-1-苯基-1,2,3,4-四氢异喹啉-2-甲酸乙酯 、 (S)-(+)-3-喹宁醇 在 sodium hydride 作用下， 以 甲苯 为溶剂， 生成 (1R,3S)-索利那新杂质2
  参考文献：
  名称：

  Synthesis and Antimuscarinic Properties of Quinuclidin-3-yl 1,2,3,4-Tetrahydroisoquinoline-2-carboxylate Derivatives as Novel Muscarinic Receptor Antagonists

  摘要：

  In the course of continuing efforts to develop potent and bladder-selective muscarinic M-3 receptor antagonists, quinuclidin-3-yl 1-aryl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives and related compounds were designed as conformationally restricted analogues of quinuclidin-3-yl benzhydrylcarbamate (8). Binding assays with rat muscarinic receptor subtypes revealed that the quinuclidin-3-yl 1-aryl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives showed high affinities for the M3 receptor, and selectivity for the M3 receptor over the M-2 receptor. Of these derivatives, (+)-(1S,3'R)-quinuclidin-3'-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monohydrochloride (9b) exhibited almost the same inhibitory activity against bladder contraction to that of oxybutynin (1), and more than 10-fold selectivity for bladder contraction versus salivary secretion, demonstrating that 9b may be useful for the treatment of symptoms associated with overactive bladder without having side effects such as dry mouth.

  DOI：

  10.1021/jm050099q
• 作为产物：
  描述：

  1-苯基-3,4-二氢异喹啉 在 sodium tetrahydroborate 、 potassium carbonate 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 60.0h， 生成 (R)-1-苯基-1,2,3,4-四氢异喹啉-2-甲酸乙酯
  参考文献：
  名称：

  Synthesis and Antimuscarinic Properties of Quinuclidin-3-yl 1,2,3,4-Tetrahydroisoquinoline-2-carboxylate Derivatives as Novel Muscarinic Receptor Antagonists

  摘要：

  In the course of continuing efforts to develop potent and bladder-selective muscarinic M-3 receptor antagonists, quinuclidin-3-yl 1-aryl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives and related compounds were designed as conformationally restricted analogues of quinuclidin-3-yl benzhydrylcarbamate (8). Binding assays with rat muscarinic receptor subtypes revealed that the quinuclidin-3-yl 1-aryl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives showed high affinities for the M3 receptor, and selectivity for the M3 receptor over the M-2 receptor. Of these derivatives, (+)-(1S,3'R)-quinuclidin-3'-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monohydrochloride (9b) exhibited almost the same inhibitory activity against bladder contraction to that of oxybutynin (1), and more than 10-fold selectivity for bladder contraction versus salivary secretion, demonstrating that 9b may be useful for the treatment of symptoms associated with overactive bladder without having side effects such as dry mouth.

  DOI：

  10.1021/jm050099q

文献信息

• [EN] PROCESS FOR PREPARING CHEMICALLY AND CHIRALLY PURE SOLIFENACIN BASE AND ITS SALTS<br/>[FR] PROCÉDÉ DE PRÉPARATION D'UNE SOLIFÉNACINE BASE DE PURETÉ CHIMIQUE ET DE PURETÉ CHIRALE ET DE SES SELS
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2009087664A1

  公开（公告）日：2009-07-16

  The present invention provides improved processes for preparing chemically and chirally pure Solifenacin base. The present invention also provides for a composition comprising of a salt of Solifenacin having at least 98 % purity. The present invention also disclose certain new salts of Solifenacin as well as well as new polymorphic forms of Solifenacin hydrochloride and Solifenacin oxalate, in pure form.

  本发明提供了改进的制备化学纯和对映纯索利那辛碱的方法。本发明还提供了一种含有至少98%纯度的索利那辛盐的组合物。本发明还披露了索利那辛的某些新盐以及索利那辛盐酸盐和索利那辛草酸盐的新多形态，均为纯形式。
• Enantioselective Synthesis of 1-Aryl Tetrahydroisoquinolines by the Rhodium-Catalyzed Reaction of 3,4-Dihydroisoquinolinium Tetraarylborates
  作者：Wei-Sian Li、Ting-Shen Kuo、Ping-Yu Wu、Chien-Tien Chen、Hsyueh-Liang Wu

  DOI：10.1021/acs.orglett.1c00198

  日期：2021.2.5

  omnipresent in biologically active molecules. Here we report on the direct asymmetric synthesis of these valuable compounds via the reaction of 3,4-dihydroisoquinolinium tetraarylborates. The dual roles of anionic tetraarylborates, which function as both prenucleophiles and stabilizers of 3,4-dihydroisoquinolinium cations, enable this rhodium(I)-catalyzed protocol to convergently provide enantioenriched 1-aryl

  1-芳基四氢异喹啉（1-芳基THIQ）在生物活性分子中无处不在。在这里，我们报告了通过3,4-二氢异喹啉四芳基硼酸酯的反应直接合成这些有价值的化合物。阴离子四芳基硼酸酯的双重作用，既充当3,4-二氢异喹啉鎓阳离子的前亲核试剂，又充当稳定剂，使这种铑（I）催化的方案能够以良好的收率（≤95％）聚合提供对映体富集的1-芳基THIQ，≤97 ％ee，如（-）-索非那新的正式合成和（-）-隐香碱I的简便合成所证明。
• Method for producing solifenacin or salts thereof
  申请人：Inakoshi Masatoshi

  公开号：US20070185329A1

  公开（公告）日：2007-08-09

  There is provided a novel method for producing solifenacin or a salt thereof which is useful as a medicine, particularly a therapeutic agent and/or a preventive agent for a urinary organ system disease such as pollakiuria or urinary incontinence. Illustratively, there are provided (1) a method for producing solifenacin in which 2-(1H-imidazolylcarbonyl)-1-phenyltetrahydroisoquinoline is used as the starting material, (2) a method for producing solifenacin succinate in which (1RS)-phenyltetrahydroisoquinoline-carboxylic acid quinuclidinyl ester is used as the starting material, (3) a method for producing solifenacin in which a lower alkyl quinuclidinyl carbonate is used as the starting material and (4) a method for producing solifenacin in which phenyltetrahydroisoquinoline-carboxylic acid secondary lower alkyl or tertiary lower alkyl ester is used as the starting material and allowed to react with an alkali metal lower alkoxide.

  提供了一种新的制备索利费南或其盐的方法，该方法可用作药物，特别是用于治疗和/或预防尿生殖器官疾病，如尿频或尿失禁的治疗剂和/或预防剂。例如，提供了以下四种方法：（1）使用2-（1H-咪唑基）-1-苯基四氢异喹啉作为起始材料制备索利费南的方法；（2）使用（1RS）-苯基四氢异喹啉-羧酸奎尼克啶酯作为起始材料制备索利费南琥珀酸盐的方法；（3）使用较低烷基奎尼库啶碳酸酯作为起始材料制备索利费南的方法；（4）使用苯基四氢异喹啉-羧酸次级较低烷基或三级较低烷基酯作为起始材料，并与碱金属较低烷氧化物反应制备索利费南的方法。
• Enantioselective Synthesis of 1-Aryl-tetrahydroisoquinolines through Iridium Catalyzed Asymmetric Hydrogenation
  作者：Farouk Berhal、Zi Wu、Zhaoguo Zhang、Tahar Ayad、Virginie Ratovelomanana-Vidal

  DOI：10.1021/ol301281s

  日期：2012.7.6

  Asymmetric hydrogenation of 1-aryl-3,4-dihydrolsoquinolines using the [IrCODCl](2)/(R)-3,5-diMe-Synphos catalyst is reported. Under mild reaction conditions, this atom-economical process provides easy access to a variety of enantioenriched 1-aryl-1,2,3,4-tetrahydroisoquinoline derivatives, which are important pharmacophores found in several pharmaceutical drug candidates, in high yields and enantiomeric excesses up to 99% after a single crystallization.
• US7829715B2
  申请人：——

  公开号：US7829715B2

  公开（公告）日：2010-11-09